Maravai Lifesciences Holdings Inc (OQ:MRVI)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 10770 Wateridge Circle Suite 200
Suite 200
SAN DIEGO CA 92121
Tel: N/A
Website: https://www.maravai.com
IR: See website
<
Key People
Robert Andrew Eckert
Chairman of the Board
William Martin
Chief Executive Officer, Director
Kevin M. Herde
Chief Financial Officer
Andrew Burch
President - Nucleic Acid Production
Rebecca Buzzeo
Executive Vice President, Chief Commercial Officer
Peter Michael Leddy
Chief Administrative Officer
Kurt Oreshack
General Counsel, Secretary
Christine Dolan
Chief Operating Officer - Biologics Safety Testing
 
Business Overview
Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities.
Financial Overview
For the nine months ended 30 September 2024, Maravai Lifesciences Holdings Inc revenues decreased 6% to $202.8M. Net loss increased from $13.1M to $118.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase of 62% to $28.6M (expense), Stock-based Compensation in R&D increase of 92% to $3.7M (expense).
Employees: 580 as of Sep 30, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $1,397M as of Sep 30, 2024
Annual revenue (TTM): $276.92M as of Sep 30, 2024
EBITDA (TTM): $13.13M as of Sep 30, 2024
Net annual income (TTM): -$224.66M as of Sep 30, 2024
Free cash flow (TTM): -$11.72M as of Sep 30, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 252,527,585 as of Nov 7, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.